Milford, MA, United States of America

Engin Ozkaynak

This inventor holds 46 USPTO granted patents and 1 published patent application, plus 1 CIPO patent, primarily in Osteogenic Proteins. Top assignees: Stryker Corporation, Creative Biomolecules, Inc., Curis, Inc.. Active years: 1991-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Engin Ozkaynak. Retrieved from https://idiyas.com/inventor/engin-ozkaynak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 46 

% Patents Active = 82.6


Average Co-Inventor Count = 4.7

ph-index = 18

Forward Citations = 1,189(Granted Patents)


Company Filing History:


Years Active: 1991-2009

Loading Chart...
Loading Chart...
Areas of Expertise:
Morphogen
Nerve Regeneration
Osteogenic Proteins
Bone Mass
Neural Cells
Epithelial Cells
Chondrogenic Protein
Nucleotide Sequences
Protein Compositions
Immune Rejection
Metabolic Bone Diseases
Cartilage
46 patents (USPTO):Explore Patents

Title: Engin Ozkaynak: Innovator in Neural and Osteogenic Therapies

Introduction

Engin Ozkaynak, based in Milford, MA, is an accomplished inventor with a significant portfolio that includes 46 patents. His innovations primarily focus on therapeutic methods for neural regeneration and bone growth, showcasing his contributions to medical science and biotechnology.

Latest Patents

Ozkaynak's recent patents include groundbreaking technologies such as morphogen-induced nerve regeneration and repair. This invention details therapeutic treatment methods, compositions, and devices aimed at maintaining neural pathways in mammals. His approach enhances neuron survival, facilitates cellular repair of damaged neurons, and stimulates neurons to preserve their differentiated phenotype. Additionally, he has developed methods for monitoring nerve tissue health and detecting neuropathies through effective morphogen delivery.

Another significant patent includes nucleic acid molecules that encode osteogenic proteins. This invention encompasses osteogenic devices that induce endochondral bone growth in mammals. It also provides essential data regarding the characteristics of osteogenic proteins, alongside methods for their production using recombinant DNA technology and synthetic protein constructs that promote bone and cartilage growth.

Career Highlights

Engin Ozkaynak has made remarkable strides in his career, with experience at notable companies such as Stryker Corporation and Creative Biomolecules, Inc. His work in these organizations has played a vital role in advancing innovative solutions in the fields of medicine and biotechnology.

Collaborations

Throughout his career, Ozkaynak has collaborated with prominent professionals, including Hermann Oppermann and David C Rueger. These partnerships have fostered the exchange of ideas and expertise, enhancing the development of his patented technologies.

Conclusion

Engin Ozkaynak's contributions to medical innovations, particularly in nerve regeneration and osteogenic therapies, underscore the importance of research and development in improving healthcare outcomes. With a robust portfolio of patents and ongoing projects, he continues to be a key player in the advancement of therapeutic technologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…